Soleno Therapeutics Ownership | Who Owns Soleno Therapeutics?


OverviewForecastRevenueFinancialsChart

Soleno Therapeutics Ownership Summary


Soleno Therapeutics is owned by 112.52% institutional investors, 3.05% insiders. Vivo capital is the largest institutional shareholder, holding 20.21% of SLNO shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.12% of its assets in Soleno Therapeutics shares.

SLNO Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSoleno Therapeutics112.52%3.05%-15.56%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vivo capital7.32M20.21%$298.53M
Carlyle group4.07M11.24%$166.36M
Janus henderson group3.36M9.28%$137.14M
Perceptive advisors3.20M8.85%$130.76M
Nantahala capital management3.08M8.51%$125.75M
Adage capital partners gp2.85M7.88%$116.45M
Avoro capital advisors2.09M5.78%$85.34M
Blackrock1.86M5.15%$76.03M
Vanguard group1.50M4.15%$61.31M
Commodore capital lp1.43M3.94%$58.14M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Vivo capital7.32M27.58%$298.53M
Carlyle group4.07M15.80%$166.36M
Nantahala capital management3.08M7.35%$125.75M
Commodore capital lp1.43M3.97%$58.14M
Ghost tree capital300.00K3.83%$12.24M
Vestal point capital, lp1.20M3.65%$48.96M
Altium capital management lp212.91K3.54%$8.69M
Perceptive advisors3.20M3.11%$130.76M
Frazier life sciences management875.67K1.67%$35.73M
Sofinnova investments554.36K1.18%$22.62M

Top Buyers

HolderShares% AssetsChange
Blackrock1.86M0.00%1.54M
Commodore capital lp1.43M3.97%1.26M
Adage capital partners gp2.85M0.22%910.57K
Nantahala capital management3.08M7.35%671.73K
Holocene advisors, lp536.45K0.09%536.45K

Top Sellers

HolderShares% AssetsChange
Vivo capital7.32M27.58%-1.10M
Assenagon asset management---729.84K
Invesco11.03K0.00%-309.00K
Ally bridge group (ny)---286.16K
Balyasny asset management---247.21K

New Positions

HolderShares% AssetsChangeValue
Holocene advisors, lp536.45K0.09%536.45K$21.89M
Polar asset management partners74.50K0.06%74.50K$3.04M
Nuveen asset management59.48K0.00%59.48K$2.43M
Norges bank57.77K0.00%57.77K$2.36M
Adar1 capital management39.93K0.31%39.93K$1.63M

Sold Out

HolderChange
Harbour investments-5.00
Entrypoint capital-135.00
Visionpoint advisory group-168.00
Pacer advisors-307.00
Aquatic capital management-900.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202415631.09%47,121,2808.78%1120.79%10330.38%24-4.00%
Jun 30, 202411910.19%43,316,98021.90%1191.24%793.95%2566.67%
Mar 31, 202410828.57%35,536,01513.14%981.18%7635.71%1515.38%
Dec 31, 20238455.56%31,409,97254.72%912.62%5633.33%1362.50%
Sep 30, 202354145.45%20,301,195318.35%5929.65%42600.00%8-

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv915.09K2.12%1.50K
Janus Henderson Global Life Sciences D627.57K1.61%38.81K
SPDR® S&P Biotech ETF624.52K1.61%6.90K
Janus Henderson Global Life Sciences639.63K1.48%60.45K
iShares Russell 2000 ETF596.83K1.38%-1.34K
Janus Henderson Glb Life Scn I2 USD476.16K1.23%21.86K
Janus Henderson US SMID Cap Growth466.95K1.20%-
Janus Henderson Triton D466.95K1.20%-
Janus Global Life Science AUSD476.16K1.10%57.56K
T. Rowe Price All-Cap Opportunities Fund335.72K0.86%28.10K

Recent Insider Transactions


DateNameRoleActivityValue
Oct 01, 2024Yen Kristen SEE REMARKSSell$16.03K
Oct 01, 2024Yen Kristen SEE REMARKSSell$137.60K
Oct 01, 2024Mackaness James H CHIEF FINANCIAL OFFICERSell$357.59K
Oct 01, 2024Mackaness James H CHIEF FINANCIAL OFFICERSell$41.66K
Oct 01, 2024Hirano Patricia C SEE REMARKSSell$137.60K

Insider Transactions Trends


DateBuySell
2024 Q4-8
2024 Q3-47
2024 Q2-10
2024 Q1-3
2023 Q4-31

SLNO Ownership FAQ


Who Owns Soleno Therapeutics?

Soleno Therapeutics shareholders are primarily institutional investors at 112.52%, followed by 3.05% insiders and -15.57% retail investors. The average institutional ownership in Soleno Therapeutics's industry, Biotech Stocks , is 47.04%, which Soleno Therapeutics exceeds.

Who owns the most shares of Soleno Therapeutics?

Soleno Therapeutics’s largest shareholders are Vivo capital (7.32M shares, 20.21%), Carlyle group (4.07M shares, 11.24%), and Janus henderson group (3.36M shares, 9.28%). Together, they hold 40.73% of Soleno Therapeutics’s total shares outstanding.

Does Blackrock own Soleno Therapeutics?

Yes, BlackRock owns 5.15% of Soleno Therapeutics, totaling 1.86M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 76.03M$. In the last quarter, BlackRock increased its holdings by 1.54M shares, a 471.09% change.

Who is Soleno Therapeutics’s biggest shareholder by percentage of total assets invested?

Vivo capital is Soleno Therapeutics’s biggest shareholder by percentage of total assets invested, with 27.58% of its assets in 7.32M Soleno Therapeutics shares, valued at 298.53M$.

Who is the top mutual fund holder of Soleno Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Soleno Therapeutics shares, with 2.12% of its total shares outstanding invested in 915.09K Soleno Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools